Abstract

Abstract Manifested as microsatellite instability (MSI), DNA mismatch repair (MMR) deficiency is known to contribute to colorectal cancer pathogenesis and drug resistance. Growing evidence indicates that MMR deficiency is also widespread among secondary cancers in patients who have received chemotherapy. It is unclear what chemotherapeutic agents cause MMR deficiency. In this study, we aim at identifying the MSI-inducing anti-cancer drugs. To facilitate the identification, we developed an in-vivo dual fluorescent reporter system in a human colorectal cancer cell model using RFP that contains a microsatellite as the MSI reporter and GFP as the cell label. Based on flow cytometric analysis, we found that test anti-cancer drugs increased the MSI frequency in a dose-dependent manner. This was confirmed by fluorescent microscopy. With the NCI recommended markers, we detected a low frequency of MSI in cells after treated with a couple, but not all, of test anti-cancer drugs. Our cell-based MSI reporter assay will facilitate large scale screens of MSI-inducing and MSI-reducing drugs/compounds, which might provide treatment strategies for controlling therapy-related secondary cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3899. doi:10.1158/1538-7445.AM2011-3899

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.